Dark

ABBV
ABBVIE INC.
stock NYSE

At Close

May 16, 2025 3:59:30 PM EDT

183.97USD+1.260%(+2.29)6,152,806

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 19, 2025 9:27:30 AM EDT

183.92USD-0.054%(-0.10)2,322

After-hours

May 16, 2025 4:55:30 PM EDT

182.54USD-0.777%(-1.43)65,750

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

04:06PM EST AbbVie Whale Trades For January 25 Benzinga

Jan 24, 2022

01:17PM EST Analyst Ratings For AbbVie Benzinga

08:01AM EST Allergan Aesthetics Announces Open Casting Call for BOTOX(r) Cosmetic PR Newswire

07:52AM EST Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $142 Benzinga

06:11AM EST A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge Benzinga

05:51AM EST FDA Approves Second Indication for Skyrizi For Active Psoriatic Arthritis Benzinga

Jan 21, 2022

04:31PM EST AbbVie Reports FDA Approval For Second Indication On SKYRIZI To Treat Adults With Active Psoriatic Arthritis Benzinga

04:30PM EST U.S. FDA Approves Second Indication for SKYRIZI(r) (risankizumab-rzaa) to Treat PR Newswire

03:33PM EST This Is What Whales Are Betting On AbbVie Benzinga

05:12AM EST $1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much Benzinga

Jan 20, 2022

09:09AM EST Barclays Maintains Equal-Weight on AbbVie, Raises Price Target to $133 Benzinga

Jan 18, 2022

06:33AM EST FDA Gives Back To Back Approval To Pfizer's & AbbVie's JAK Inhibitors For Atopic Dermatitis Benzinga

05:14AM EST FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older Benzinga

Jan 14, 2022

01:11PM EST AbbVie Says FDA Approves RINVOQ To Treat Adults, Children 12 Years And Older With Refractory, Moderate To Severe Atopic Dermatitis Benzinga

01:10PM EST U.S. FDA Approves RINVOQ(r) (upadacitinib) to Treat Adults and Children 12 PR Newswire

11:59AM EST AbbVie Option Alert: Mar 4 $140 Calls Sweep (23) near the Ask: 265 @ $1.951 vs 4 OI; Earnings 2/2 Before Open Ref=$133.75 Benzinga

Jan 12, 2022

09:44AM EST BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $153 Benzinga

Jan 11, 2022

09:55AM EST Price To Earnings Ratio Insights For AbbVie Benzinga

08:54AM EST AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025. RTTNews

08:48AM EST AbbVie Confirms Guidance Of More Than $15 Bln In Combined Risk-Adj. Sales For Rinvoq And Skyrizi In 2025 RTTNews

08:47AM EST AbbVie Reaffirms FY25 Guidance For Rinvoq, Skyrizi Sales Over $15B Benzinga

08:45AM EST AbbVie Confirms Guidance of Greater Than $15 Billion in Combined Risk-Adjusted PR Newswire

07:47AM EST ACELYRIN Appoints Melanie Gloria As COO RTTNews

07:45AM EST ACELYRIN Appoints Melanie Gloria as Chief Operating Officer PR Newswire

Jan 10, 2022

11:55AM EST New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion PR Newswire

10:17AM EST Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years Benzinga

09:47AM EST Wednesday Is Your Last Chance To Buy AbbVie Before The Dividend Payout Benzinga

Jan 7, 2022

03:06PM EST Watching AbbVie; Hearing UBS Says AbbVie Not Planning To Present CF Data Next Week Benzinga

01:04PM EST AbbVie Reports Submission Of Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis to FDA, European Medicines Agency Benzinga

09:38AM EST AbbVie Submits Applications For Upadacitinib In RTTNews

09:02AM EST AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA And EMA RTTNews

09:00AM EST Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) PR Newswire

Jan 5, 2022

02:04PM EST Analyst Ratings For AbbVie Benzinga

09:27AM EST Mizuho Maintains Buy on AbbVie, Raises Price Target to $154 Benzinga

08:00AM EST AbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call PR Newswire

Jan 4, 2022

08:39AM EST AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy. RTTNews

08:19AM EST AbbVie : FDA Grants Breakthrough Therapy Designation To Telisotuzumab Vedotin For Previously Treated NSCLC RTTNews

08:16AM EST AbbVie Reports FDA Granted Breakthrough Therapy Designation To Telisotuzumab Vedotin For Previously-Treated Non-Small Cell Lung Cancer Benzinga

08:15AM EST Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer PR Newswire

08:01AM EST AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire

Jan 3, 2022

06:22AM EST Teva Suffers Loss In New York's Opioid Trial Benzinga

Dec 30, 2021

11:27AM EST AbbVie Option Alert: Feb 18 $140 Calls Sweep (29) near the Ask: 310 @ $2.8 vs 29495 OI; Earnings 2/2 Before Open [est] Ref=$136.57 Benzinga

Dec 27, 2021

12:11PM EST What Are Whales Doing With AbbVie Benzinga

Dec 23, 2021

02:14PM EST AbbVie Option Alert: Jan 21 $140 Calls Sweep (36) near the Ask: 585 @ $0.89 vs 7824 OI; Earnings 2/2 Before Open [est] Ref=$133.55 Benzinga

Dec 22, 2021

06:01PM EST ETF BAD Debuts With A Focus On Cannabis Stocks, Gambling And Alcohol Benzinga

Dec 21, 2021

08:12AM EST The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail Benzinga

Dec 17, 2021

10:18AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 Benzinga

07:49AM EST Goldman Sachs Initiates Coverage On AbbVie with Neutral Rating, Announces Price Target of $113 Benzinga

Dec 16, 2021

01:21PM EST AbbVie Whale Trades For December 16 Benzinga

09:00AM EST Allergan Aesthetics Closes Acquisition Of Soliton RTTNews

08:58AM EST Allergan Aesthetics Completes Acquisition of Soliton PR Newswire

Dec 15, 2021

11:31AM EST FDA Approves AbbVie's JAK Inhibitor Application For Active Psoriatic Arthritis Benzinga

08:03AM EST The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO Benzinga

Dec 14, 2021

07:59PM EST AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. RTTNews

06:19PM EST RINVOQ(r) (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic PR Newswire

09:29AM EST Genentech's Polivy Combination Reduces Risk Of Disease RTTNews

Dec 12, 2021

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 10, 2021

09:24AM EST AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial Benzinga

07:50AM EST The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares Benzinga

06:32AM EST SpringWorks Therapeutics Reports Clinical Collab With AbbVie To Evaluate Nirogacestat In Combo With ABBV-383 In Patients with Relapsed, Refractory Multiple Myeloma, No Terms Disclosed Benzinga

Dec 9, 2021

09:51PM EST Where AbbVie Stands With Analysts Benzinga

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:48PM EST AbbVie's Allergan Announces Availability Of VUITY 1.25% In Prescription Pharmacies Benzinga

09:47PM EST Wells Fargo Initiates Coverage On AbbVie with Overweight Rating, Announces Price Target of $165 Benzinga

09:37PM EST Biosimilar Player Alvotech To Go Public Via $2.5B Oaktree SPAC Merger Benzinga

09:20AM EST Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S. RTTNews

09:04AM EST Allergan Says FDA-Approved Eye Drop To Treat Age-Related Blurry Near Vision VUITY Now Available RTTNews

09:02AM EST FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now Available PR Newswire

Dec 6, 2021

08:50AM EST AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12. RTTNews

08:32AM EST AbbVie : Upadacitinib Achieved Primary &Secondary Endpoints In Phase 3 Induction Study In Patients With Crohn's Disease RTTNews

08:32AM EST AbbVie Announces Upadacitinib Achieved Primary And Key Secondary Endpoints In First Phase 3 Induction Study In Patients With Crohn's Disease Benzinga

08:30AM EST Upadacitinib (RINVOQ(r)) Achieved Primary and Key Secondary Endpoints in First PR Newswire

06:54AM EST AbbVie Adds New Warning To Rinvoq (JAK Inhibitor) Label For Rheumatoid Arthritis Benzinga

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 3, 2021

04:19PM EST AbbVie Provides Update On RINVOQ For The Treatment Of Rheumatoid Arthritis In The U.S. Benzinga

04:16PM EST AbbVie Provides Update on RINVOQ(r) (upadacitinib) for the Treatment of PR Newswire

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Dec 1, 2021

03:38PM EST AbbVie Shares Quiet Following FDA AccessData.gov Listing For Co.'s Depakote ER Shows FDA Approved Drug Benzinga

Nov 30, 2021

04:47PM EST AbbVie Submits Application For Risankizumab In Moderate To Severe Crohn's Disease To European Medicines Agency Benzinga

08:08AM EST AbbVie Submits Application For Risankizumab In Moderate To Severe Crohn's Disease To EMA RTTNews

08:05AM EST AbbVie Submits Application for Risankizumab (SKYRIZI(r)) in Moderate to Severe PR Newswire

Nov 23, 2021

10:17AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021 Benzinga

08:20AM EST AbbVie To Present At Evercore ISI Conference On Thursday, Dec. 2, 2021 At 12:10 p.m. EST Benzinga

08:17AM EST AbbVie To Present At Evercore ISI Conference Benzinga

08:00AM EST AbbVie to Present at the Piper Sandler Healthcare Conference PR Newswire

06:36AM EST Societe Generale Upgrades AbbVie to Buy, Announces $172 Price Target Benzinga

Nov 19, 2021

08:03AM EST Allergan Aesthetics To Present Data From Its Aesthetic Portfolio RTTNews

08:00AM EST Allergan Aesthetics To Present Data From Its Leading Aesthetic Portfolio At The PR Newswire

Nov 18, 2021

09:02AM EST New Literature Review Highlights Economic Benefits Associated with Achieving PR Newswire

08:37AM EST AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. Following the agreement, Quebec is the first province to reimburse the combination treatment. RTTNews

07:55AM EST Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3 Benzinga

07:06AM EST AbbVie Announces First Provincial Reimbursement For VENCLEXTA With Obinutuzumab For Patients With Previously Untreated Chronic Lymphocytic Leukemia In Quebec Benzinga

07:06AM EST AbbVie Announces Reimbursement For VENCLEXTA With Obinutuzumab For Patients With Previously Untreated CLL In Quebec RTTNews

Nov 17, 2021

10:59AM EST Europe Approves AbbVie's Skyrizi For Second Indication Benzinga

07:53AM EST The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment Benzinga

02:57AM EST AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. RTTNews

02:30AM EST AbbVie: European Commission Approves SKYRIZI For Adults With Active Psoriatic Arthritis RTTNews

02:06AM EST Commission Approval of SKYRIZI(r) (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis PR Newswire

Nov 15, 2021

08:30AM EST Allergan Aesthetics Celebrates Third Annual BOTOX(r) Cosmetic PR Newswire

Nov 10, 2021

08:34AM EST AbbVie, University Of Chicago Extend Research Collaboration To Support Preclinical Oncology Research Through 2025 Benzinga

08:30AM EST AbbVie, University of Chicago Extend Research Collaboration to Support PR Newswire

08:03AM EST AbbVie to Present at the Wolfe Research Healthcare Conference PR Newswire

Nov 9, 2021

11:46AM EST AbbVie Presents New Efficacy Data On Upadacitinib (RINVOQ) In People With Active Psoriatic Arthritis And Axial Involvement At ACR Convergence 2021 Benzinga

08:48AM EST AbbVie Presents New Efficacy Data On Upadacitinib In People With Active Psoriatic Arthritis And Axial Involvement RTTNews

08:45AM EST AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ(r)) in People with PR Newswire

08:31AM EST Response to RINVOQ(r) (Upadacitinib) Among Patients with Rheumatoid Arthritis PR Newswire

Nov 8, 2021

08:34AM EST Allergan To Present New Data From Eye Care Portfolio RTTNews

08:32AM EST AbbVie's Allergan To Present At AAO 2021 Annual Meeting Nov. 12-15 Benzinga

08:30AM EST Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting PR Newswire

Nov 6, 2021

03:20PM EDT Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More Benzinga

Nov 5, 2021

10:26AM EDT AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis. RTTNews

10:12AM EDT AbbVie Says Phase 3 Trials Data On Risankizumab Shows Greater Improvements In Psoriatic Arthritis Signs RTTNews

10:09AM EDT AbbVie Highlights Presentation Of Integrated Efficacy, Safety Data From 2 Phase 3 Trials On Risankizumab In Psoriatic Arthritis At American College Of Rheumatology Benzinga

10:07AM EDT AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on PR Newswire

Nov 4, 2021

09:08AM EDT AbbVie To Highlight New Advances In Blood Cancer Research And Expanding Oncology Pipeline At ASH Annual Meeting RTTNews

09:05AM EDT AbbVie to Highlight New Advances in Blood Cancer Research and Expanding PR Newswire

Nov 2, 2021

02:28PM EDT AbbVie Option Alert: Dec 17 $125 Calls at the Ask: 6910 @ $0.77 vs 971 OI; Ref=$116.88 Benzinga

Nov 1, 2021

12:08PM EDT UPDATE: SVB Leerink On AbbVie Price Target Cut: Firm Warns On Faster Humira Erosion, Though Slightly Offset By Neuro Upside With Forecasted EPS CAGR For FY21-25 Estimated At 2%; Notes 8.5% Dividend Increase Ahead Of Humira LOE & $17B Free Cash Flow YTD Benzinga

10:21AM EDT AbbVie Late Friday Announced FDA Approved VUITY 1.25% To Treat Presbyopia Benzinga

09:54AM EDT Barclays Maintains Equal-Weight on AbbVie, Raises Price Target to $118 Benzinga

08:32AM EDT AbbVie Highlights Research From Rheumatology Portfolio At ACR Convergence 2021 RTTNews

08:31AM EDT AbbVie Highlights Innovative Research From Its Rheumatology Portfolio at ACR PR Newswire

08:28AM EDT Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $124 Benzinga

06:43AM EDT SVB Leerink Maintains Outperform on AbbVie, Lowers Price Target to $135 Benzinga

Oct 30, 2021

05:28AM EDT The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. RTTNews

Oct 29, 2021

05:32PM EDT ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) PR Newswire

12:44PM EDT Why AbbVie Shares Are Rising Today Benzinga

09:34AM EDT From AbbVie Q3 Earnings Conference Call: Co. Has Not Yet Observed Significant Impact To Use Of Its Rheumatoid Arthritis Drug Following FDA Safety Communication Benzinga

09:33AM EDT From AbbVie Q3 Earnings Conference Call: Sees Q4 Sales Nearing $15B vs $15.02B Estimate Benzinga

08:36AM EDT Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). RTTNews

08:05AM EDT While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2021. RTTNews

08:00AM EDT The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs Benzinga

07:53AM EDT AbbVie : Cariprazine Meets Primary Endpoint In Phase 3 Study As Adjunctive Treatment For Major Depressive Disorder RTTNews

07:51AM EDT AbbVie's Cariprazine Met Primary Endpoint In Phase 3 Study As Adjunctive Treatment For Major Depressive Disorder Benzinga

07:50AM EDT AbbVie's Cariprazine (VRAYLAR(r)) Met Primary Endpoint in Phase 3 Study as an PR Newswire

07:50AM EDT AbbVie (ABBV) Declares Quarterly Dividend of $ 1.41, Record Date 1/14/2022 RTTNews

07:49AM EDT AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year. RTTNews

07:43AM EDT AbbVie Q3 GAAP EPS $1.78; Adj EPS $3.33 RTTNews

07:42AM EDT UPDATE: AbbVie Raises FY21 Adj. EPS Guidance From $12.52-$12.62 To $12.63-$12.67 vs $12.59 Estimate Benzinga

07:41AM EDT AbbVie Raises Guidance Benzinga

07:41AM EDT AbbVie Reports Third-Quarter 2021 Financial Results PR Newswire

07:41AM EDT AbbVie Q3 Adj. EPS $3.33 Beats $3.22 Estimate, Sales $14.34B Beat $14.32B Estimate Benzinga

03:41AM EDT Earnings Scheduled For October 29, 2021 Benzinga

Oct 28, 2021

03:56PM EDT FDA Restricts Sale, Approves New Labeling Of Breast Implants Benzinga

11:37AM EDT A Preview Of AbbVie's Earnings Benzinga

08:54AM EDT AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease. RTTNews

08:18AM EDT AbbVie : ABBV-951 Shows Improvement In Controlling Motor Fluctuations In Phase 3 Trial In Advanced Parkinson's Disease RTTNews

08:16AM EDT AbbVie Reports ABBV-951 Showed Improvements In Controlling Motor Fluctuations vs Oral Levodopa/Carbidopa Medication In Phase 3 Trial For Parkinson's Benzinga

08:15AM EDT Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease PR Newswire

Oct 27, 2021

10:04AM EDT Price Over Earnings Overview: AbbVie Benzinga

Oct 26, 2021

08:39AM EDT Allergan To Present New Data On Investigational AGN-190584 For Treatment Of Presbyopia Nov. 3-6 Benzinga

08:31AM EDT Allergan To Present New Data On Investigational AGN-190584 For Treatment Of Presbyopia RTTNews

08:30AM EDT Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 PR Newswire

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 22, 2021

04:26PM EDT A-List Executive Team, Big-Name Backers Fail to Lift Abbisko IPO Benzinga

Oct 21, 2021

12:10PM EDT AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial Benzinga

Oct 19, 2021

09:54AM EDT The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. RTTNews

Oct 15, 2021

08:53AM EDT AbbVie's Risankizumab Gets CHMP Positive Opinion For RTTNews

08:37AM EDT AbbVie Receives CHMP Positive Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis RTTNews

08:36AM EDT AbbVie Reports Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis In EU Benzinga

08:35AM EDT Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) PR Newswire

Oct 14, 2021

12:00PM EDT This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers Benzinga

Oct 11, 2021

02:21PM EDT Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program Benzinga

11:07AM EDT Cannabis Movers & Shakers: Clairvoyant Therapeutics, Eaze, Leafly, Chalice Brands Benzinga

08:42AM EDT Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer PR Newswire

Oct 7, 2021

04:17PM EDT Former Tilray CEO Joins Psychedelics Company Benzinga

01:24PM EDT AbbVie Says Health Canada Approves the Use of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis Benzinga

01:23PM EDT Health Canada Approves the Use of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis Benzinga

11:11AM EDT AbbVie Presents New Upadacitinib Data In Atopic Dermatitis Benzinga

08:34AM EDT AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies RTTNews

08:19AM EDT AbbVie's RINVOQ Meets Primary And Secondary Endpoints In Phase 3 Study For Non-Radiographic Axial Spondyloarthritis RTTNews

08:17AM EDT AbbVie Reports Upadacitinib Met Primary, Most Secondary Endpoints In Phase 3 Study For Non-Radiographic Axial Spondyloarthritis Benzinga

08:17AM EDT AbbVie's RINVOQ Meets Primary And All Ranked Secondary Endpoints In Phase 3 Study In Ankylosing Spondylitis RTTNews

08:17AM EDT AbbVie's Upadacitinib (RINVOQ(r)) Met Primary and Most Ranked Secondary PR Newswire

08:15AM EDT AbbVie's RINVOQ(r) (upadacitinib) Met Primary and All Ranked Secondary PR Newswire

Oct 5, 2021

08:00AM EDT AbbVie to Host Third-Quarter 2021 Earnings Conference Call PR Newswire

05:57AM EDT AbbVie Presents New Upadacitinib Data In Atopic Dermatitis Benzinga

05:41AM EDT AbbVie Received FDA Approval for Venclexta for Efficacy Under NDA 208573 on Monday Benzinga

Oct 2, 2021

06:07PM EDT AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week PR Newswire

Sep 30, 2021

03:04PM EDT AbbVie Presents New Upadacitinib Data In Atopic Dermatitis Benzinga

03:02PM EDT AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis Benzinga

09:56AM EDT AbbVie Presents Late-Breaking Data On Risankizumab In Psoriatic Arthritis RTTNews

09:49AM EDT AbbVie Presents Late-Breaking Data On Risankizumab (SKYRIZI) In Psoriatic Arthritis At 30th European Academy Of Dermatology And Venereology (EADV) Congress Benzinga

09:46AM EDT Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress PR Newswire

09:37AM EDT AbbVie: New Analysis Show RINVOQ's Potential To Alleviate RTTNews

08:34AM EDT AbbVie Highlights Presentation Of New Analyses Evaluating RINVOQ In Atopic Dermatitis Across Patient Characteristics And Body Regions At EADV Virtual Congress Benzinga

08:33AM EDT AbbVie Presents Analyses Evaluating RINVOQ In Atopic Dermatitis Across Patient Characteristics And Body Regions RTTNews

08:30AM EDT Dermatitis Across Patient Characteristics and Body Regions at EADV Virtual Congress PR Newswire

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

10:57AM EDT AbbVie Granted FDA Approval For QULIPTA Benzinga

08:37AM EDT FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie Benzinga

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

09:36PM EDT The U.S. Food and Drug Administration approved AbbVie's (ABBV) Qulipta or atogepant for the preventive treatment of episodic migraine in adults. RTTNews

06:43PM EDT FDA Approves QULIPTA(tm) (atogepant), the First and Only Oral CGRP Receptor PR Newswire

Sep 27, 2021

08:30AM EDT Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey PR Newswire

Sep 25, 2021

12:58PM EDT Barron's Latest Picks And Pans: Healthcare Roundtable Picks, Dividend Aristocrats And More Benzinga

Sep 24, 2021

01:16PM EDT Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug Benzinga

Sep 23, 2021

01:58PM EDT AbbVie Option Alert: Jan 21 $125 Calls at the Ask: 8050 @ $0.76 vs 12202 OI; Earnings 10/29 Before Open [est] Ref=$108.205 Benzinga

01:53PM EDT AbbVie Option Alert: Jan 21 $125 Calls at the Ask: 8800 @ $0.76 vs 12202 OI; Earnings 10/29 Before Open [est] Ref=$108.11 Benzinga

08:51AM EDT AbbVie Presents New Data Analyses For Growing Dermatology Portfolio RTTNews

08:46AM EDT AbbVie To Present New Data Analyses For Dermatology Portfolio At 30th European Academy Of Dermatology And Venereology Congress Benzinga

08:45AM EDT AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th PR Newswire

Sep 20, 2021

09:58AM EDT AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by data from three phase 3 studies - ADVANCE, MOTIVATE and FORTIFY. RTTNews

09:15AM EDT AbbVie Submits Application To FDA For SKYRIZI For Treatment Of Patients 16 Yrs And Older With Severe Crohn's Disease RTTNews

09:12AM EDT AbbVie Reports Submission Of Regulatory Application To FDA For Risankizumab-rzaa For Treatment Of Patients 16 Years+ With Moderate To Severe Crohn's Disease Benzinga

09:10AM EDT for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease PR Newswire

Sep 16, 2021

12:42PM EDT AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis Benzinga

08:03AM EDT AbbVie Submits Regulatory Applications To FDA And EMA For Upadacitinib For Active Ulcerative Colitis Treatment RTTNews

08:01AM EDT (RINVOQ(r)) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire

08:01AM EDT AbbVie Submits Regulatory Applications To FDA And EMA For Upadacitinib Benzinga

Sep 13, 2021

10:57AM EDT Why Regenxbio Shares Are Trading Higher Today Benzinga

07:41AM EDT Lake Bluff-based biopharmaceutical company AbbVie (ABBV) has joined hands with Rockville-headquartered REGENXBIO Inc. (RGNX), a clinical-stage biotechnology firm to develop and sell RGX-314, an eye-care therapy, the companies said in a statement on Monday. RTTNews

06:33AM EDT AbbVie, REGENXBIO Form Strategic Deal, To Combine Eye Care And Gene Therapy RTTNews

06:31AM EDT AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones Benzinga

06:30AM EDT AbbVie and REGENXBIO Announce Eye Care Collaboration PR Newswire

Sep 10, 2021

03:50PM EDT AbbVie (ABBV) Declares Quarterly Dividend of $ 1.30, Record Date 10/15/2021 RTTNews

10:31AM EDT AbbVie Declares Quarterly Dividend Of $1.30/shr; Payable November 15/record October 15 RTTNews

10:28AM EDT AbbVie Declares Quarterly Dividend PR Newswire

09:00AM EDT AbbVie to Highlight Its Leadership in Movement Disorders at the International PR Newswire

Sep 9, 2021

08:01AM EDT AbbVie to Present at the Morgan Stanley Healthcare Conference PR Newswire

07:04AM EDT Genmab, AbbVie: The Lancet Publishes Trial Results Of Epcoritamab In Patients With R/r B-cell Non-Hodgkin's Lymphoma RTTNews

07:03AM EDT Clinical Trial of Investigational Epcoritamab In Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Published In The Lancet Benzinga

07:00AM EDT with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet PR Newswire

07:00AM EDT Clinical Trial of Investigational Epcoritamab (DuoBody(r)-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet Business Wire

Sep 8, 2021

09:12AM EDT AbbVie To Present Data From Migraine Portfolio At 2021 International Headache Congress RTTNews

09:11AM EDT AbbVie to Present Data From Its Migraine Portfolio at the 2021 International PR Newswire

Sep 4, 2021

04:04PM EDT The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More Benzinga

Sep 2, 2021

08:35AM EDT FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know Benzinga

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

03:49PM EDT Why AbbVie's Stock Is Trading Lower Today Benzinga

11:46AM EDT AbbVie Shares Down ~11% For Session, Traders Circulate Earlier Updated FDA Warning On Co.'s Xeljanz, Xeljanz XR Arthritis, Ulcerative Colitis Medicine Benzinga

11:16AM EDT AbbVie Option Alert: Fri $110 Puts Sweep (39) near the Ask: 354 @ $0.998 vs 737 OI; Earnings 10/29 Before Open [est] Ref=$111.48 Benzinga

Aug 26, 2021

10:07AM EDT AbbVie Gets Positive Recommendation From Canadian Panel For VENCLEXTA In Combination With Azacitidine For AML RTTNews

10:03AM EDT AbbVie Receives Reimbursement Recommendation from Canadian Agencies for Drugs and Technology in Health (CADTH) pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for VENCLEXTA (venetoclax) with azacitidine for Acute Myeloid Leukemia Patient Benzinga

08:09AM EDT The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO Benzinga

Aug 25, 2021

03:08PM EDT AbbVie Option Alert: Oct 15 $130 Calls Sweep (22) above Ask!: 1000 @ $0.641 vs 2384 OI; Ref=$120.58 Benzinga

Aug 24, 2021

08:18AM EDT AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. The company noted that this marks the fourth EC-approved indication for RINVOQ. RTTNews

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

08:08AM EDT AbbVie Says European Commission Approves RINVOQ (upadacitinib) As First JAK Inhibitor In EU For Treatment Of Both Adults And Adolescents With Moderate To Severe Atopic Dermatitis Benzinga

08:03AM EDT EU Oks RINVOQ As First JAK Inhibitor For Treatment Of Both Adults &Adolescents With Moderate To Severe Atopic Dermatitis RTTNews

08:01AM EDT the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis PR Newswire

Aug 20, 2021

06:41AM EDT SVB Leerink Maintains Outperform on AbbVie, Raises Price Target to $148 Benzinga

Aug 19, 2021

01:11PM EDT AbbVie Says U.S. District Court For District Of Delaware Issued Decision Holding Patent Rights Owned By Unit Pharmacyclics Benzinga

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

05:31PM EDT New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine Benzinga

05:29PM EDT New England Journal of Medicine Publishes 12-Week Results from Study Evaluating PR Newswire

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

01:50PM EDT Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma Benzinga

Aug 9, 2021

01:50PM EDT AbbVie, Mission Therapeutics Pick Alzheimer's & Parkinson's Targets In Neurodegenerative Disease Collaboration Benzinga

08:59AM EDT AbbVie (ABBV) announced that SKYRIZI, an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis. The new SKYRIZI 150 mg pen comes with audible cues to help guide the administration process and an indicator to signal when administration is complete. RTTNews

document.getElementById("HZDcFB").onerror = function(){this.style.display='none';}; .dark-mode .xSvHxx{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .xSvHxx{ color: #333333; background-color: white; border: 2px solid #333333; }ABBVABBVIE INC.stock NYSE

ABBV
ABBVIE INC.
stock NYSE